Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 26, 2018
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based ProposalGiuseppe Pelosi, Mauro Papotti, Luisella Righi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
The Oncologist|January 23, 2025
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancerFerdinandos Skoulidis, Bob T Li, Maximilian Hochmair, et al.
Cancer Treatment Reviews|October 27, 2018
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Martina Imbimbo, Margaret Ottaviano, Milena Vitali, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME databaseGiovanni Leuzzi, Federica Sabia, Claudia Proto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas databaseClaudio Sini, Alessandro Russo, Diego Cortinovis, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 26, 2018
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based ProposalGiuseppe Pelosi, Mauro Papotti, Luisella Righi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
The Oncologist|January 23, 2025
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancerFerdinandos Skoulidis, Bob T Li, Maximilian Hochmair, et al.
Cancer Treatment Reviews|October 27, 2018
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Martina Imbimbo, Margaret Ottaviano, Milena Vitali, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME databaseGiovanni Leuzzi, Federica Sabia, Claudia Proto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas databaseClaudio Sini, Alessandro Russo, Diego Cortinovis, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
Pageof 17